ReutersReuters · 实盘可交易 · 做多市场:美股▲ 赚 +1.09% · 已结算把握 5/10标签:reuters
北京时间·🕒 发布 07-02 06:45:07时区推断·⟳ 抓取 07-02 10:56:10·⚡ 决策 07-03 00:08:09 +13h11m·116.6 天前
FDA批准Vertex/CRISPR的Casgevy扩展至2岁以上SCD和TDT儿童患者
FDA将Casgevy适用年龄从12岁以上扩至2岁以上，Vertex称美国新增约5500名儿童适用患者，属于一手官方确认的标签扩展利好。
📄 原文Reuters↗ 原文
美国FDA批准Vertex基因疗法用于治疗两岁及以上儿童的镰状细胞病 FDA批准Vertex基因疗法Casgevy扩大适应症至2岁及以上镰状细胞病儿童，有望拓宽市场并提振业绩。
The U.S. Food and Drug Administration approved expanded use of Vertex Pharmaceuticals' (VRTX.O) gene therapy in childre…
▲ 赚 +1.09%入场 07-01 盘后首笔 @55.40 → 离场 07-02 常规开盘 @56.18
决策后走势暂无图(这条腿还没有复盘打分的日线切片)
💡 交易逻辑FDA将Casgevy适用年龄从12岁以上扩至2岁以上，Vertex称美国新增约5500名儿童适用患者，属于一手官方确认的标签扩展利好。
怎么买 限价买入 不高于 59.5、当日有效，不成交作废
怎么卖 止盈 +7%(半仓)/+14%(清仓) · 止损 -6% · 时间止损 5日
失效/反转 若公司或FDA口径显示2岁扩龄不覆盖主要SCD/TDT商业人群、支付/治疗中心无法接入新增儿童患者，或后续披露Casgevy放量继续显著低于预期，则退出。
不做 Vertex Pharmaceuticals（VRTX.US）
Vertex是直接受益方但市值约1320亿美元，Casgevy 2025年收入约1.16亿美元且放量受治疗流程限制，本次扩龄短线增量不足以构成市值级重定价。
不做 Vertex Inc.（VERX.US）
VERX为税务软件公司，与FDA批准的Vertex/CRISPR Casgevy基因疗法无业务关系，属于同名误映射。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
分时走势
做多 CRSP.US CRISPR Therapeutics
建仓日早于近 30 天,只有日线图
成交明细 · 纸面
做多 CRSP.US CRISPR Therapeutics
| 收益状态 | +1.09% 已平仓 |
|---|---|
| 进场成交 | 2026-07-01 · 盘后首笔 · 07-02 06:50 北京 · @55.4 · 成交 0% |
| 离场成交 | 2026-07-02 · 常规开盘 · @56.18 |
| 毛收益 | +1.41% |
| 成本 | +0.32% |
| 净收益 | +1.09% |
| 计入收益 | +0.00% |
| 建仓日 | 2026-07-01 · 进场不早于新闻时刻 + 2 分钟 |
| 契约提示 | LIMIT_AND_CHASE |
收益口径 event_time_plus_2min_10min_walk_open_topup_to_next_open_exchange_calendar_fill_model_local_notional_v9 · method_id m8db1cbc8f2d · 截至 2026-10-27 13:51
研究档案
消息传播链
- ASH儿科SCD/TDT关键数据已在2025年12月披露，说明临床方向并非全新。
- Vertex披露5-11岁儿童关键研究数据并称与成人和青少年疗效一致，市场已有标签扩展预期。
- Vertex公告FDA批准Casgevy用于2岁及以上SCD/TDT患者，并称美国新增约5500名儿童适用患者。
- Reuters在美股盘后报道FDA批准扩龄，形成主流媒体扩散。
- 2026-07-02 12:04 ET市场反应Futu/stock_quote非一手信号复判时美股盘中可成交，CRSP上涨约5.97%，VRTX上涨约4.36%，事件已有首日反应但不能单独判定充分price-in。市场反应:CRSP.US 58.94美元，日涨5.97%；VRTX.US 519.72美元，日涨4.36%。
关键理由
- FDA将Casgevy适用年龄从12岁以上扩至2岁以上，Vertex称美国新增约5500名儿童适用患者，属于一手官方确认的标签扩展利好。
- CRISPR Therapeutics（CRSP.US）按合作协议分享Casgevy 40%净利润/亏损，市值约58亿美元，相比Vertex约1320亿美元更有事件弹性。
- 量级上，Casgevy 2025年收入约1.16亿美元、2025年全年64例输注；本次新增患者池理论上很大，但治疗中心、支付和采集输注节奏决定收入爬坡较慢，因此只适合小仓条件单而非追高重仓。
主要风险
- Casgevy商业化仍处早期且执行链条复杂，2025年收入相对Vertex 2026Q1单季约29.9亿美元收入基数很小，对Vertex短线市值级拉动不足。
- 儿科数据和监管提交预期在2025年12月、2026年6月已被市场提前讨论，CRSP/VRTX当天已上涨，存在中等price-in和追价风险。
反向证据
- 做多前查反向 · 来源 kb_search · 日期 2026-05-05 · 影响 weakens
KB命中券商观点称Casgevy动能增强但也提示销售可能不及预测、临床和诉讼风险，未发现足以否定本次扩龄利好的反证。
检索:CRSP recent downside risk downgrade litigation Casgevy sales slow 2026 原文 ↗ - 做多前查反向 · 来源 kb_search · 日期 2026-02-09 · 影响 weakens
KB命中Vertex被下调至Hold的观点，理由包括Journavx和Casgevy仍偏小众、对下一增长阶段贡献存疑，削弱VRTX交易吸引力。
检索:Vertex recent downside risk Casgevy sales slow clinical failure 2026 VX-993 VRTX 原文 ↗
工具调用 · 历史记录,结果未知(4 种)
- kb_search · 结果未知
- stock_quote · 结果未知
- normalize_ticker · 结果未知
- validate_order · 结果未知
原文全文
展开原文 · 1,567 字
The U.S. Food and Drug Administration approved expanded use of Vertex Pharmaceuticals' (VRTX.O) gene therapy in children as young as two with inherited blood disorders, including sickle cell disease, the first such treatment cleared for this age group.
Casgevy, a one-time treatment made from a patient's own blood stem cells, was previously approved for patients aged 12 and older with sickle cell disease or transfusion-dependent beta thalassemia.
Here are further details: -
Sickle cell disease is a painful, inherited blood disorder in which the body makes sickle-shaped hemoglobin, preventing red blood cells from properly carrying oxygen to the body's tissues.
In a trial of children aged five to under 12 with sickle cell disease, all eight evaluable patients had no severe vaso-occlusive crises or painful episodes for at least 12 straight months within the first 24 months of infusion.
In beta thalassemia, eight of nine evaluable children achieved transfusion independence for 12 consecutive months, with a median duration of 20.1 months.
The FDA granted approval to Vertex in 53 days after filing under the Commissioner's National Priority Voucher, its new fast-track program designed to shorten review time for a drug application.
In 2023, the FDA approved Vertex's and Genetix Biotherapeutics' gene therapies for sickle cell disease in patients 12 years and older.
Other long-term treatment options for sickle cell disease include bone marrow transplant, which requires matching donors, and the chemotherapy drug hydroxyurea.
Casgevy, a one-time treatment made from a patient's own blood stem cells, was previously approved for patients aged 12 and older with sickle cell disease or transfusion-dependent beta thalassemia.
Here are further details: -
Sickle cell disease is a painful, inherited blood disorder in which the body makes sickle-shaped hemoglobin, preventing red blood cells from properly carrying oxygen to the body's tissues.
In a trial of children aged five to under 12 with sickle cell disease, all eight evaluable patients had no severe vaso-occlusive crises or painful episodes for at least 12 straight months within the first 24 months of infusion.
In beta thalassemia, eight of nine evaluable children achieved transfusion independence for 12 consecutive months, with a median duration of 20.1 months.
The FDA granted approval to Vertex in 53 days after filing under the Commissioner's National Priority Voucher, its new fast-track program designed to shorten review time for a drug application.
In 2023, the FDA approved Vertex's and Genetix Biotherapeutics' gene therapies for sickle cell disease in patients 12 years and older.
Other long-term treatment options for sickle cell disease include bone marrow transplant, which requires matching donors, and the chemotherapy drug hydroxyurea.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。